Clinical trial
Rituximab Treatment in Sjogren's Syndrome
NCT00363350 · University Medical Center Groningen, Other · Completed
Key facts
| NCT number | NCT00363350 |
|---|---|
| Title | Rituximab Treatment in Sjogren's Syndrome |
| Official title | Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial |
| Lead sponsor | University Medical Center Groningen, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Sjogren's Syndrome |
| Intervention type | Drug |
| Interventions | rituximab (anti-CD20) |
| Enrollment | 30 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | Feb 24, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: